![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 11
Zeitschriftenartikel
Bian, Dongliang; Jiang, Siming; Xiong, Yicheng; Qi, Mengfan; Wu, Jiawei; Addeo, Alfredo; Yamauchi, Yoshikane; Manapov, Farkhad; Dempke, Wolfram C. M.; Vannucci, Jacopo; Di Federico, Alessandro; Xu, Xiaoxiong und Chen, Linsong
(2022):
Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis.
In: Translational Lung Cancer Research, Bd. 11, Nr. 8
Dempke, Wolfram C. M. und Fenchel, Klaus
(2021):
Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?-a narrative review.
In: Translational Lung Cancer Research, Bd. 10, Nr. 6: S. 2667-2682
Dempke, Wolfram C. M. und Reck, Martin
(2021):
KEAP1/NRF2 (NFE2L2) mutations in NSCLC-Fuel for a superresistant phenotype?
In: Lung Cancer, Bd. 159: S. 10-17
Wang, Yanhui; Xiao, Jiawei; Jiang, Wenna; Zuo, Duo; Wang, Xia; Jin, Yu; Qiao, Lu; An, Haohua; Yang, Lexin; Dumoulin, Daphne W.; Dempke, Wolfram C. M.; Best, Sarah A. und Ren, Li
(2021):
BCKDK alters the metabolism of non-small cell lung cancer.
In: Translational Lung Cancer Research, Bd. 10, Nr. 12: S. 4459-4476
Uciechowski, Peter und Dempke, Wolfram C. M.
(2020):
Interleukin-6: A Masterplayer in the Cytokine Network.
In: Oncology, Bd. 98, Nr. 3: S. 131-137
Manz, Kirsi M. 
ORCID: https://orcid.org/0000-0002-7740-4076; Fenchel, Klaus; Eilers, Andreas; Morgan, Jonathan; Wittling, Kirsten und Dempke, Wolfram C. M. ORCID: https://orcid.org/0000-0002-7683-1017
(14. Dezember 2019):
Efficacy and Safety of Approved First-Line Tyrosine
Kinase Inhibitor Treatments in Metastatic Renal Cell
Carcinoma: A Network Meta-Analysis.
In: Advances in therapy, Bd. 37: S. 730-744
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-7740-4076; Fenchel, Klaus; Eilers, Andreas; Morgan, Jonathan; Wittling, Kirsten und Dempke, Wolfram C. M. ORCID: https://orcid.org/0000-0002-7683-1017
(14. Dezember 2019):
Efficacy and Safety of Approved First-Line Tyrosine
Kinase Inhibitor Treatments in Metastatic Renal Cell
Carcinoma: A Network Meta-Analysis.
In: Advances in therapy, Bd. 37: S. 730-744
[PDF, 1MB]
Dempke, Wolfram C. M.; Fenchel, Klaus; Uciechowski, Peter und Dale, Stephen P.
(2017):
Second- and third-generation drugs for immuno-oncology treatment-The more the better?
In: European Journal of Cancer, Bd. 74: S. 55-72
Dempke, Wolfram C. M.; Fenchel, Klaus; Uciechowski, Peter und Chevassut, Timothy
(2017):
Targeting Developmental Pathways: The Achilles Heel of Cancer?
In: Oncology, Bd. 93, Nr. 4: S. 213-223
Fenchel, Klaus; Dale, Stephen P. und Dempke, Wolfram C. M.
(2016):
Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?
In: Translational Lung Cancer Research, Bd. 5, Nr. 4: S. 373-376
Dempke, Wolfram C. M. und Fenchel, Klaus
(2016):
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
In: Translational Lung Cancer Research, Bd. 5, Nr. 5: S. 538-542
Fenchel, Klaus; Sellmann, Ludger und Dempke, Wolfram C. M.
(2016):
Overall survival in non-small cell lung cancer-what is clinically meaningful?
In: Translational Lung Cancer Research, Bd. 5, Nr. 1: S. 115-119